Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "novel transcript, antisense to STX4" (ENSG00000299404) is a non-coding RNA annotated as transcribed from the opposite strand of the STX4 (syntaxin 4) gene locus. Antisense transcripts like this one typically do not encode proteins but can influence the expression and regulation of their sense gene counterparts through a variety of mechanisms, such as chromatin modification, altering transcript stability, or modulating splicing. There is evidence that in general, antisense non-coding RNAs can play roles in regulating gene expression, fine-tuning mRNA abundance, and influencing chromatin architecture; however, the specific functions and disease associations of this particular transcript have not been characterized in the literature. It is not considered a therapeutic target, nor is it currently used as a biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antisense RNA to syntaxin 4 (STX4).